Insider sales are routine post-earnings option exercises by the CEO and a director, representing a negligible fraction of market cap. The strong Q1 beat and raised guidance dominate the narrative. Monitor for any additional insider sales in the next 30 days; if they accelerate beyond $10M, it could signal a top.
Price Chart
Executive Summary
Kiniksa Pharmaceuticals CEO Sanj K. Patel and Director Barry D. Quart sold a combined $4.42M in open-market shares on April 28-30, 2026, following the company's strong Q1 2026 earnings report. The sales represent ~0.11% of market cap and are largely tied to the exercise of stock options, making them routine portfolio diversification rather than a bearish signal.
Key Financial Metrics
Key Facts
- CEO Sanj K. Patel sold 99,320 shares for $5.10M total across April 28-30, all tied to option exercises
- Director Barry D. Quart sold 13,099 shares for $656K on April 28, also tied to option exercise
- Total open-market sales: $4.42M, representing ~0.11% of $4.1B market cap
- Sales occurred 2 days after Q1 2026 earnings beat: revenue $214.3M (+56% YoY), net income $22.6M (+166% YoY)
- ARCALYST guidance raised to $930-$945M from $900-$920M; company remains debt-free with $468.1M cash
Financial Impact
Total insider sales of $4.42M, or 0.11% of market cap — trivial relative to company size
Risk Factors
- CEO sold 99K shares — if this pattern continues, it could indicate peak sentiment
- ARCALYST growth may slow as the recurrent pericarditis market matures
- KPL-387 Phase 2 data in 2H 2026 is a binary catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KNSA-1777588407335 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $76.00 | awaiting T+60 | — | $85.02 (+11.88%) |
Oct 27, 2026 today | Press Release | $75.00 | awaiting T+60 | — | $85.02 (+13.36%) |
Oct 22, 2026 4d ago | 8-K | $76.73 | awaiting T+60 | — | $85.02 (+10.80%) |
Oct 22, 2026 4d ago | Press Release | $80.79 | awaiting T+60 | — | $85.02 (+5.24%) |
Sep 3, 2026 7w ago | 144 | $77.91 | awaiting T+60 | — | $85.02 (+9.13%) |
Jul 28, 2026 13w ago | 8-K | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $85.02 (+7.02%) |
Jul 28, 2026 13w ago | Press Release | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $85.02 (+7.02%) |
May 26, 2026 21w ago | 8-K | $51.84 $78.47 | ▲ +51.37% | ▲ +49.49% | $85.02 (+64.00%) |
May 1, 2026 25w ago | 8-K | $57.62 $80.92 | ▲ +40.44% | ▲ +38.58% | $85.02 (+47.55%) |
Apr 28, 2026 25w ago | 144 | $52.99 $62.84 | ▼ −18.59% | ▼ −14.48% | $85.02 (−60.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers